NCHS Data Brief 360:18 Kermansaravi M, Lainas P, Shahmiri SS, Yang W, Jazi AD, Vilallonga R, Antozzi L, Parmar C, Kassir R, Chiappetta S, Zubiaga L, Vitiello A, Mahawar K, Carbajo M, Musella M, Shikora S (2022) The first survey addressing patients with BMI over 50: a survey of 789 bariatric surgeons
Providing your insurance provider with detailed information about your health condition, weight loss history, and the recommended surgical procedure can help them assess your eligibility for coverage
Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials
This information can support a more informed conversation with your provider about which compounded GLP-1 formulation, starting dose, or titration schedule may align with your genetic and clinical profile
Underlying genetic or hormonal hair loss can still progress, which is why personalised assessment is important
Expert Team Our team has extensive experience in regenerative therapies and peptide treatments